Ionis Pharmaceuticals Announces Board Retirements and New Appointment

Ionis Pharmaceuticals ( (IONS) ) just unveiled an update.

Ionis Pharmaceuticals announced on March 9, 2026, that long-serving directors B. Lynne Parshall and lead independent director Joseph H. Wender will retire from its board at the end of their terms, effective June 4, 2026. Their departures mark the exit of two influential figures who have helped shape Ionis’ strategy and governance over more than two decades, including Parshall’s prior service as chief operating officer and chief financial officer.

To support continuity and bolster expertise during what the company describes as a period of rapid growth and pipeline progress, Ionis said that veteran healthcare banker and policy advisor Peter N. Reikes will rejoin its board on June 4, 2026. Reikes, who previously served as an Ionis director from 2018 to 2021 and held senior roles at ARPA-H, the U.S. Food and Drug Administration and multiple investment banks, brings extensive financial, regulatory and industry experience expected to reinforce the company’s board-level oversight as it advances its growth agenda.

The most recent analyst rating on (IONS) stock is a Buy with a $110.00 price target. To see the full list of analyst forecasts on Ionis Pharmaceuticals stock, see the IONS Stock Forecast page.

Spark’s Take on IONS Stock

According to Spark, TipRanks’ AI Analyst, IONS is a Neutral.

The score is held down primarily by weak financial performance (ongoing losses, negative free cash flow, and materially higher leverage). This is partly offset by a strong and optimistic earnings-call outlook driven by pipeline/launch momentum and growth guidance, while technicals are mixed and valuation remains constrained by negative earnings.

To see Spark’s full report on IONS stock, click here.

More about Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. is a biotechnology company specializing in RNA‑targeted medicines, with marketed therapies and a leading pipeline in neurology, cardiometabolic disease and other high‑need indications. The Carlsbad, Calif.-based group is also advancing gene-editing approaches, leveraging three decades of expertise in disease biology and nucleic acid drug development.

Ionis focuses on developing and commercializing therapies for serious diseases, positioning itself as a fully integrated biotech with both discovery capabilities and commercial operations. Its strategy centers on innovation in RNA technologies to sustain growth and maintain a competitive edge in high-value therapeutic markets.

Average Trading Volume: 2,154,102

Technical Sentiment Signal: Buy

Current Market Cap: $12.23B

See more insights into IONS stock on TipRanks’ Stock Analysis page.